- Eli Lilly and Company
- 07 January 2026 13:35:05
Source: Sharecast
According to the Wall Street Journal, a deal for Ventyx, which specialises in developing pills that can treat inflammatory diseases, could be announced imminently.
San Diego-based Ventyx had a market value of a little over $500m as of Tuesday afternoon.
The company specialises in the development of pills to treat diseases like Crohn's and rheumatoid arthritis. The pills have also shown promise treating neurodegenerative conditions like Parkinson's, as well as heart-related conditions, the WSJ said.
One of Ventyx's drug candidates is currently in mid-stage testing for the treatment of cardiovascular disease associated with obesity.
The WSJ said Ventyx has been developing treatments targeting a complex of proteins, called NLRP3, that researchers have found plays an important role in the body's inflammatory response and immune diseases where that response goes haywire.
Ventyx has two experimental drugs that seek to inhibit the out-of-control inflammatory activity.
At 1310 GMT, Ventyx shares were up 56% at $15.67 in pre-market trade.